TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

| While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline. | BigHat ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Israeli computational biology company Evogene is looking to the clouds to secure the computational power it needs to develop ...

A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Johnson & Johnson MedTech’s Abiomed announced that its compressible, expandable heart pump has cleared a pivotal trial, and ...

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a ...